main content start
¿Le gustó este contenido?
Cáncer de mama 11m 14s

Oral Selective Estrogen Receptor Degraders for ESR-1 Mutant Metastatic Breast Cancer

Publicado11 Jul 2022
Endocrine therapy is the mainstay in the management of patients with Hormone receptor positive (ER+ve) Metastatic Breast Cancer. Tumor progression in ER+ve MBC could be attributed to genomic alterations such as ESR mutations.
biomarkers esr1 mutation fulvestrant hormone receptor positive mbc serd

Disclaimer: The Views/Opinions expressed and/or opinions provided in Videos and other content on MedEnrich Website are those of respective speakers. They do not purport to reflect the opinion or views of Dr.Reddy’s Laboratories Limited or its affiliates (collectively Dr.Reddy’s)in any manner whatsoever and accordingly ,Dr.Reddys does not recommend , endorse or make any representation about the veracity and appropriateness of the views ,opinions/ information on MedEnrich website. Content on MedEnrich website may discuss uses and dosage for therapeutic product that may not have been approved in by the relevant regulatory agencies in your country. Dr.Reddy’s does not support , endorse or encourage any off-label use. Please refer to approved label before prescribing.

Ventajas de registrarse en MedEnrich
Contenido en línea en varios formatos
Contenido personalizado
Acceso ilimitado a todas las funciones
Hi, can I help?
Chat de ayudaX
Equipo de soporte
¡Hola! ¿Cómo puedo ayudarlo/a hoy?
Por favor seleccione alguna de las siguientes opciones.

Buscar información

Problemas con el inicio de sesión o registro

Compartir un comentario